Serum biomarkers in patients with relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss)

PLoS One. 2015 Mar 26;10(3):e0121737. doi: 10.1371/journal.pone.0121737. eCollection 2015.

Abstract

Introduction: Previous studies suggest a role for eotaxin-3, TARC/CCL17 and IgG4 in newly-diagnosed patients with eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss) with highly active disease. The role of these biomarkers in relapsing disease is unclear.

Methods: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio were determined in serum samples from a longitudinal cohort of patients with EGPA (105 visits of 25 patients). Epidemiological, clinical and laboratory data were available for all visits.

Results: At the first visit, 80% of patients were using glucocorticoids and 68% additional immunosuppressive drugs. Disease flares were seen at 18 visits. The median BVAS and BVAS/WG scores at time of relapse were 4 and 2, respectively. None of the biomarkers tested were useful to discriminate between active disease and remission. Patients treated with prednisone had lower eotaxin-3 and eosinophil levels compared to patients not taking glucocorticoids irrespective of disease activity. Use of immunosuppressive agents was not associated with biomarker levels.

Conclusions: Serum levels of TARC/CCL17, eotaxin-3, IgG4, and IgG4/IgG ratio do not clearly differentiate active and inactive disease in established EGPA. Defining biomarkers in EGPA remains a challenge especially during times of glucocorticoid use.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Biomarkers
  • Chemokine CCL17 / blood
  • Chemokine CCL26
  • Chemokines, CC / blood
  • Churg-Strauss Syndrome / blood*
  • Churg-Strauss Syndrome / drug therapy
  • Churg-Strauss Syndrome / immunology
  • Churg-Strauss Syndrome / pathology
  • Eosinophils
  • Female
  • Humans
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Recurrence

Substances

  • Biomarkers
  • CCL26 protein, human
  • Chemokine CCL17
  • Chemokine CCL26
  • Chemokines, CC
  • Immunoglobulin G
  • Immunosuppressive Agents